Reducing the 10–21 day expansion phase in CAR T-cell therapy production lowers the dose required and speeds up delivery, addressing the fact that 30% of annual therapies go unused due to patient deterioration.
Reducing the 10–21 day expansion phase in CAR T-cell therapy production lowers the dose required and speeds up delivery, addressing the fact that 30% of annual therapies go unused due to patient deterioration.